Vaxart to Present at Global Medical Meetings in April
March 28 2019 - 8:00AM
Business Wire
Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology
company developing oral recombinant vaccines that are administered
by tablet rather than by injection, today announced participation
in two upcoming global medical meetings in April.
Vaxart will present the following:
- Poster presenting potential new immune
correlates of protection for influenza observed in the Phase 2
challenge study of its H1 influenza oral tablet vaccine at the
upcoming International Society for Influenza and other Respiratory
Virus Diseases’ (ISIRV) Immunological Assays and Correlates of
Protection for Next Generation Influenza Vaccines conference,
taking place from March 31-April 2, 2019 in Siena, Italy
- New scientific data supporting the
importance of mucosal IgA to protect against influenza and a
summary of data from the Phase 2 challenge study of its H1
influenza oral tablet vaccine at the upcoming Influenza Vaccines
for the World (IVW) 2019, taking place from April 2-4, 2019 in
Edinburgh, Scotland
Details of the presentations are as follows:
Immunological Assays and Correlates of Protection for Next
Generation Influenza Vaccines Conference
Poster Title: Cell-Mediated Immunity Correlates of
Protection in an Influenza Challenge Study following Vaccination
via Oral Tablet in HumansDate & Time: Monday, April 1,
2019 at 5:30 PM CETAuthors: Keith Gottlieb, et
al.Session: Poster Presentation
Influenza Vaccines for the World 2019
Presentation Title: Recent progress in novel,
cross-reactive and universal influenza vaccinesDate &
Time: Tuesday, April 2, 2019 at 3:40 PM GMTAuthors: Sean
TuckerSession: Session 5: Influenza Vaccines Developments II
– Antigen Design and Characterization
Presentation Title: IgA is critical for protection
against influenza following mucosal deliveryDate & Time:
Wednesday, April 3, 2019 at 12:30 PM GMTAuthors: Nikita
KolhatkarSession: Session 7: Influenza vaccines developments
in mechanisms of action & correlates of protection
The Phase 2 study was completed with support from Biomedical
Advanced Research and Development Authority (BARDA). Vaxart
received a $13.9 million contract from BARDA in September 2015 to
support the advanced development of more effective influenza
vaccines to ultimately improve seasonal and pandemic influenza
preparedness. The contract was increased to $15.7 million in
2017.
The project has been funded in whole or in part with federal
funds from the Department of Health and Human Services’ Office of
the Assistant Secretary for Preparedness and Response; Biomedical
Advanced Research and Development Authority under Contract No.
HHSO100201500034C.
About Vaxart
Vaxart is a clinical-stage biotechnology company focused on
developing oral recombinant protein vaccines based on its
proprietary oral vaccine platform. Vaxart’s vaccines are designed
to generate broad and durable immune responses that protect against
a wide range of infectious diseases and may also be useful for the
treatment of chronic viral infections and cancer. Vaxart’s vaccines
are administered using a convenient room temperature-stable tablet,
rather than by injection. Vaxart believes that tableted vaccines
are easier to distribute and administer than injectable vaccines
and have the potential to significantly increase vaccination rates.
Vaxart’s development programs include oral tablet vaccines that are
designed to protect against norovirus, seasonal influenza and
respiratory syncytial virus (RSV), as well as a therapeutic vaccine
for human papillomavirus (HPV). For more information, please visit
www.vaxart.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. All statements, other
than statements of historical facts, included in this press release
regarding our strategy, prospects, plans and objectives, results
from preclinical and clinical trials, commercialization agreements
and licenses, beliefs and expectations of management are
forward-looking statements. These forward-looking statements may be
accompanied by such words as “believe,” “could,” “potential,”
“will” and other words and terms of similar meaning. Examples of
such statements include, but are not limited to, statements
relating to the Vaxart’s ability to develop and commercialize its
product candidates and clinical results and trial data; and
Vaxart’s expectations with respect to the advantages it believes
its oral vaccine platform can offer over injectable alternatives,
particularly for mucosal pathogens such as norovirus, flu and RSV.
Vaxart may not actually achieve the plans, carry out the intentions
or meet the expectations or projections disclosed in our
forward-looking statements and you should not place undue reliance
on these forward-looking statements. Actual results or events could
differ materially from the plans, intentions, expectations and
projections disclosed in the forward-looking statements. Various
factors could cause actual results or events to differ materially
from these forward-looking statements, including Vaxart’s ability
to raise sufficient capital to fund the continued development of
its product candidates and complete its planned studies and trials,
that Vaxart’s product candidates may not be approved by the FDA or
non-U.S. regulatory authorities; that, even if approved by the FDA
or non-U.S. regulatory authorities, Vaxart’s product candidates may
not achieve broad market acceptance; that Vaxart may experience
manufacturing issues and delays; and other risks described in the
“Risk Factors” sections of Vaxart’s Quarterly and Annual Reports
filed with the SEC. Vaxart does not assume any obligation to update
any forward-looking statements, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190328005156/en/
Carl MauchStern Investor
Relations212-362-1200vaxart@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024